Skip to main content
AUPH logo

AUPH · Aurinia Pharmaceuticals Inc. · Earnings Calls, Transcripts & Webcasts

Track AUPH — free
$14.70 -0.19 (-1.28%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$1.97B
Shares
134.00M
Volume · Nov 20 1.34M Avg daily vol (3M) 864.89K

Aurinia Pharmaceuticals Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Aurinia Pharmaceuticals Inc. (AUPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY25 · Q4
2026-02-26
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Confident tone Diagnostic and treatment paradigm strategy Combination therapy research Competitive landscape and market growth
Revenue
$77.11M
▲ 28.8% YoY
Diluted EPS
$1.53
▲ 15200% YoY
Gross margin
88.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Confident tone Aritinercept development Raised 2025 financial guidance LUPKYNIS commercial growth
Revenue
$73.47M
▲ 8.4% YoY
Diluted EPS
$0.23
▲ 130% YoY
Gross margin
88.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Confident tone Revenue and earnings momentum LUPKYNIS commercial growth Aritinercept (AUR200) pipeline
Revenue
$70.01M
▲ 22.4% YoY
Diluted EPS
$0.16
▲ 1500% YoY
Gross margin
89.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-30
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript
Confident tone LUPKYNIS commercial growth AUR200 pipeline (Phase 1 SAD) ACR/EULAR/KDIGO guidelines and first-line positioning
Revenue
$62.47M
▲ 24.2% YoY
Diluted EPS
$0.16
Gross margin
86.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call
Confident tone AUR200 pipeline development 2025 financial guidance LUPKYNIS revenue growth
Revenue
$59.87M
▲ 32.8% YoY
Diluted EPS
$0.01
Gross margin
90.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2024 Earnings Call Transcript
Positive tone LUPKYNIS commercial performance Japan regulatory approval and Otsuka partnership ENLIGHT-LN registry and real-world evidence
Revenue
$67.77M
▲ 24.3% YoY
Diluted EPS
$0.10
Gross margin
91.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2024 Earnings Call Transcript
Confident tone Revenue and commercial growth AUR200 pipeline development Otsuka partnership and international expansion
Revenue
$57.19M
▲ 37.8% YoY
Diluted EPS
$0.01
Gross margin
84.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript
Confident tone Lupus nephritis market opportunity and awareness LUPKYNIS commercial performance Corporate restructuring and cost reduction
Revenue
$50.30M
▲ 46.2% YoY
Diluted EPS
$-0.07
Gross margin
84.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript
Positive tone Patient growth metrics LUPKYNIS commercial performance Physician and patient education
Revenue
$45.09M
▲ 58.6% YoY
Diluted EPS
$-0.19
Gross margin
88.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript
Revenue
$54.52M
▼ 2.3% YoY
Diluted EPS
$-0.09
Gross margin
87.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call Transcript
Revenue
$41.49M
▲ 47.2% YoY
Diluted EPS
$-0.08
Gross margin
96.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Call Transcript
Revenue
$34.41M
▲ 59.1% YoY
Diluted EPS
$-0.18
Gross margin
98.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Call Transcript
Revenue
$28.43M
▲ 21.5% YoY
Diluted EPS
$-0.18
Gross margin
95.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Call Transcript
Revenue
$55.78M
▲ 280.3% YoY
Diluted EPS
$-0.06
Gross margin
95.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2022 Earnings Call Transcript
Revenue
$28.19M
▲ 325.8% YoY
Diluted EPS
$-0.25
Gross margin
94.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2022 Earnings Call Transcript
Revenue
$21.62M
▲ 2266% YoY
Diluted EPS
$-0.27
Gross margin
98.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2021 Earnings Call Transcript
Revenue
$23.40M
▼ 53.2% YoY
Diluted EPS
$-0.25
Gross margin
97.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2021 Earnings Call Transcript
Revenue
$14.67M
▲ 50475.9% YoY
Diluted EPS
$-0.39
Gross margin
98.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2021 Earnings Call Transcript
Revenue
$6.62M
▲ 22727.6% YoY
Diluted EPS
$-0.37
Gross margin
95.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2021 Earnings Call Transcript
Revenue
$914,000
▲ 2946.7% YoY
Diluted EPS
$-0.40
Gross margin
94.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2020 Earnings Call Transcript
Revenue
$50.03M
▲ 172417.2% YoY
Diluted EPS
$-0.06
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2020 Earnings Call Transcript
Revenue
$29,000
▼ 87.4% YoY
Diluted EPS
$-0.34
Gross margin
100.0%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Earnings Call Transcript
Revenue
$29,000
▲ 0% YoY
Diluted EPS
$-0.24
Gross margin
100.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Date not confirmed
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2020 Earnings Call Transcript
Revenue
$30,000
▲ 0% YoY
Diluted EPS
$-0.23
Gross margin
100.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 webcasts
Key facts CIK 1600620 CUSIP 05156V102 13F (30d) 285 filings 254 filers Visit website Investor relations